YMTX Stock Overview
Yumanity Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of treatments for neurodegenerative diseases caused by protein misfolding.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Yumanity Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$13.23 |
| 52 Week High | US$26.45 |
| 52 Week Low | US$6.65 |
| Beta | 0 |
| 1 Month Change | 2.16% |
| 3 Month Change | 15.24% |
| 1 Year Change | -41.30% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -91.45% |
Recent News & Updates
Recent updates
Shareholder Returns
| YMTX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -8.3% | -4.7% | -3.7% |
| 1Y | -41.3% | -2.7% | 20.2% |
Return vs Industry: YMTX underperformed the US Biotechs industry which returned -4.2% over the past year.
Return vs Market: YMTX underperformed the US Market which returned 14.1% over the past year.
Price Volatility
| YMTX volatility | |
|---|---|
| YMTX Average Weekly Movement | 9.0% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: YMTX has not had significant price volatility in the past 3 months.
Volatility Over Time: YMTX's weekly volatility has decreased from 16% to 9% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 41 | Richard Peters | www.yumanity.com |
Yumanity Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of treatments for neurodegenerative diseases caused by protein misfolding. The company focuses on discovering disease-modifying therapies to treat neurodegenerative diseases, including Parkinson’s disease, dementia with Lewy bodies, multiple system atrophy, amyotrophic lateral sclerosis, and frontotemporal lobar degeneration. Its lead program is YTX-7739, a novel small molecule that is in Phase I clinical trial for the treatment of Parkinson’s disease and related disorders of a-synuclein.
Yumanity Therapeutics, Inc. Fundamentals Summary
| YMTX fundamental statistics | |
|---|---|
| Market cap | US$143.63m |
| Earnings (TTM) | -US$32.00m |
| Revenue (TTM) | US$4.84m |
29.7x
P/S Ratio-4.5x
P/E RatioIs YMTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| YMTX income statement (TTM) | |
|---|---|
| Revenue | US$4.84m |
| Cost of Revenue | US$12.45m |
| Gross Profit | -US$7.60m |
| Other Expenses | US$24.40m |
| Earnings | -US$32.00m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.95 |
| Gross Margin | -156.97% |
| Net Profit Margin | -660.75% |
| Debt/Equity Ratio | 0% |
How did YMTX perform over the long term?
See historical performance and comparison